TD Asset Management
RIGL icon

TD Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

TD Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-7,780
Closed -$279K – 1306
2013
Q3 		$279K Buy
7,780
+1,040
+15% +$38K ﹤0.01% 1131
2013
Q2 		$225K Buy
+6,740
New +$305K ﹤0.01% 1109

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TD Asset Management's RIGL Position: Q4 2013 in Review

TD Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2013, closing a stake of 7,780 shares — an estimated $279K sold.

TD Asset Management first reported a position in RIGL in Q2 2013 and held it in 2 quarters. The position peaked at $279K in Q3 2013. 100 funds tracked by Wall St. Rank hold RIGL as of Q4 2013.

  • TD Asset Management reported no remaining Rigel Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • TD Asset Management sold 7,780 Rigel Pharmaceuticals shares in Q4 2013, an estimated $279K.
  • TD Asset Management first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • TD Asset Management's Rigel Pharmaceuticals position peaked at $279K in Q3 2013.
  • 100 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2013.

Based on TD Asset Management's 13F filing for Q4 2013, filed 7 Feb 2014.